Affiliation:
1. 1Department of Medical Microbiology and Parasitology, PMB, 4400, Osogbo, Nigeria
2. 2Department of Biomedical Science, College of Health Sciences, Ladoke Akintola University of Technology, PMB, 4400, Osogbo, Nigeria
Abstract
AbstractA survey of 104 sexually active young females tested on on cervico-vaginal swabs showed that 26 of the females (25%) had vulvovaginal candidiasis with a species distribution of Candida isolates accounting for 13 (50%) with C. albicans, 6 (23%) with C. glabrata, 1 (4%) with C. krusei, and 6 (23%) with C. tropicalis. Of the 26 (25 %) subjects that were positive for VVC, 8 (7.8 %) were symptomatic and 18 (18.8 %) were asymptomatic. However, distribution among different age groups revealed an increase in the 23–27 age group. The comparative analysis of sensitivity of the given fungi to the number of antimycotic preparations used revealed the following: in fluconazole, 2 (7.8%) isolates were sensitive, 5 (19.2%) were susceptible and dose dependent, and 19 (73%) were resistant. For voriconazole, 4 (18.4%) isolates were sensitive, 6 (23.1%) were susceptible and dose dependent, and 16 (61.5%) were resistant. For nystatin, 5 (19.2%) isolates were sensitive, 10 (38.5%) were susceptible and dose dependent, and 11 (42.3%) were resistant. It appears that Candida isolates have a variable resistance response, but 19 (73%) had maximum resistance of the isolated fungi of the genus Candida to fluconazole. Therefore, further studies on the evaluation of combination therapy should be considered for a better outcome in treatment of vulvovaginal candidiasis.
Reference23 articles.
1. Nwokedi E, Omole-Ohonsi A (2007): Current Clinical Review of Vulvovaginal Candidiasis (VVC). Journal of Medicine and Rehabilitation: 1: 28–32
2. Onifade AK, Olorunfemi OB (2005): Epidemiology of Vulvo-vaginal Candidiasis in Female Patients in Ondo State Government Hospitals. International Journal of Food, Agriculture and Environment: 3: 118–119
3. Sexually transmitted diseases treatment guidelines (2006): Centers for Disease Control and Prevention. MMWR Recomm. Rep. 55(RR-11): 1–95
4. Sobel J, Chaim W, Nagappan V, Leaman D (2003): Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 189: 1:297–300
5. Sobel JD (1998): Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses 41(suppl. 2): 18–22
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献